Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Hemostemix Inc
V.HEM
Alternate Symbol(s):
HMTXF
Healthcare
Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP...
-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:HEM)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 17, 2022 11:35am
$HMTXF sent-off investors flabbergasted with the recent run
HMTXF today marked a rather gallant opening on the OTC market, and is currently trading at $0.2125 with an up-hill motion in the market
(17)
•••
christiano
X
View Profile
View Bullboard History
Post by
christiano
on Jun 17, 2022 10:55am
$HEM with a remarkable rally on the venture exchange
$HEM started off fine on the TSX-V index and is currently trading with an intact pace and continuity, the shares are trading at $0.28 with no losses
Access North American AND Australian listed and Pre-IPO opportunities – here!
posted Dec 02, 2024 9:00am by
Stockhouse Publishing Ltd.
-
|
For the first time on Stockhouse, Canadian investors can access ASX-listed opportunities through our partnership with HotCopper in Australia, opening doors to high-potential investments at the click of a button. Learn more here… ...read more
(24)
•••
robert345
X
View Profile
View Bullboard History
Post by
robert345
on Jun 17, 2022 10:35am
$HEM announced equity offering of 15 million units sharehold
Hemostemix in a recent press release has announced a non-brokered private placement of around 15 million units for its existing shareholders mentioned in the recent press release by the company
...more
(3)
•••
DRJENNY
X
View Profile
View Bullboard History
Post by
DRJENNY
on Jun 16, 2022 3:00pm
Rick Groome addition as a financial advisor could benefit
Mr. Rick Groome, a financial advisor, was recently inducted to the Hemostemix family, according to Smeenk, who stated that Rick facilitates the organization to reach out to a broader base of investors
...more
(3)
•••
DRJENNY
X
View Profile
View Bullboard History
Post by
DRJENNY
on Jun 16, 2022 2:35pm
CEO Hemostemix emphasizes the increasing volatility of $HEM.
Thomas Smeenk on the latest update stated “for the stem cell space it is the right time to take a bite of the apple” Thomas later said the management board have invested about $4.5 Million in the
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 16, 2022 1:45pm
ACP-01 ample efficiency in curing cardiac diseases
ACP-01 (Angiogenic cell precursors) is on track its 2’nd phase clinical trial to treat patient with limb ischemia but has also proved to be a boon for patients with cardiomyopathy
(36)
•••
WalterTheDawg
X
View Profile
View Bullboard History
Comment by
WalterTheDawg
on Jun 16, 2022 1:13pm
RE: $HEM ACP-01 clinical trial scores
You spammers should probably stick to snippets of NRs and stay away from distorting the truth. That was an interim result from 12 patients and without unblinding we don't even know if all the
...more
(17)
•••
MatthewDavies
X
View Profile
View Bullboard History
Post by
MatthewDavies
on Jun 16, 2022 1:02pm
“The common shares to be issued on certain prospectus”- $HEM
$HEM Hemostemix Inc. The Common Shares will be issued in reliance on certain prospectus exemptions available under Canadian securities legislation and will be subject to a four month and one day hold
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 16, 2022 11:21am
Hemostemix has a 15 million market capitalization.
Hemostemix Inc. (OTCQB: HMTXF) is a clinical-stage biotechnology company with expertise in the research and development plus manufacturing and commercialization of blood-driven cell therapies for
...more
(24)
•••
robert345
X
View Profile
View Bullboard History
Post by
robert345
on Jun 16, 2022 11:01am
$HEM ACP-01 clinical trial scores
$HEM has already announced the results from its 2nd phase CLI trial under the guidance of Hemostemix itself, which has noted healing of ulcers and resolution of the pain of ischemia, which occurred in
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 2:55pm
Hemostemix Inc. Market Graph
Hemostemix Inc. holds a significant role in TSX-V with its greater difference between the lower and higher range of trading today is $0.28-$0.30. In the last 52 weeks it is $0.13-$0.42.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 12:48pm
Hemostemix Inc. Stock overview
Hemostemix is a Canadian based biotechnology company listed on TSX-V currently sits at $0.30 with a trading volume over $13K.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 12:34pm
Hemostemix information regarding intellectual property
Hemostemix Inc. recently announced the settlement of all litigation with aspire Health Service Inc., AJIA Global, LLC and Alan Jacobs, Jed Wood, Randi Wood, Blake Wood, Kyle Makofka, Reginald
...more
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 12:15pm
The Exercise Price option granted by $HEM
According to Hemostemix Inc., all the stock options were granted with an exercise price of $0.17 per common share and have an expiry date of February 28, 2027.
(67)
•••
Jon9800
X
View Profile
View Bullboard History
Post by
Jon9800
on Jun 15, 2022 12:02pm
The Peer review Articles by Hemostemix
The company has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden
Debt-Free Cannabis Company Set for Next Stage of Growth
Rig Count Soars as Utilization Surpasses Industry Averages
Learn How this Company is Disrupting Poin-of-Care Testing.
Unique Battery Metals opportunity in Quebec